ArticleClinical pharmacokinetics2026
Structured Evaluation of Model-Informed Precision Dosing of Mycophenolic Acid and Tacrolimus in Pediatric Patients with Kidney Disease.
Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06095895 (Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveMycophenolic acid and tacrolimus are frequently used in kidney transplant recipients and patients with nephrotic syndrome. For both drugs, therapeutic drug monitoring is recommended. Model-informed precision dosing, not only uses population pharmacokinetic data but also increases flexibility. To optimize treatment with mycophenolic acid and tacrolimus using a limited number of samples, we evaluated model-informed precision dosing for both drugs.
methodsWe performed the following steps: (1) selection of population pharmacokinetic models; (2) retrospective evaluation using real-world data; and (3) evaluation of limited sampling strategies, (4) prospective evaluation of the predictive performance by predicting an area under the concentration-time curve from time zero to 12 h at a next occasion (3 months later). Acceptable bias and imprecision were defined as a mean prediction error and a normalized root mean square error of less than 25%.
resultsA 3‑point sampling schedule (t = 0, t = 1, t = 2 h) provided accurate area under the concentration-time curve from time zero to 12 h estimation for both drugs, with mean prediction error and normalized root mean square error of 0.1% (- 0.3 to 0.6%) and 21.0% (7.1-34.8%) for mycophenolic acid, and 0.2% (0.03-0.4%) and 7.8% (3.0-12.6%) for tacrolimus. Substantial between-occasion variability limited the prediction of future area under the concentration-time curve from time zero to 12 h. For mycophenolic acid, the mean prediction error was 15.4% (14.4-16.4%) and the normalized root mean square error was 48.6% (18.2-79.0%). For tacrolimus, corresponding values were 64.2% (59.7-68.7%) for mean prediction error and 210% (37.1-383%) for normalized root mean square error.
conclusionsModel-informed precision dosing-guided limited sampling strategies are feasible for estimation of current exposure using similar sampling times for mycophenolic acid and tacrolimus. Accurate long-term prediction is not possible, underscoring the need for repeated therapeutic drug monitoring. CLINICAL
trial registrationNCT06095895.
Identifiers
42814375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.